rubitecan

DRUG16 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Astex Pharmaceuticals, Inc., Gynecologic Oncology Group

Conditions

Bladder CancerBrain and Central Nervous System TumorsBreast CancerColorectal CancerEsophageal CancerGastric CancerGastrointestinal Stromal TumorLung Cancer

Phase 1

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

CompletedNCT00113113

Astex Pharmaceuticals, Inc.Tumors

Start: 2001-08-31Target: 54Updated: 2024-08-02

Phase 2

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

WithdrawnNCT00006267

Gynecologic Oncology GroupOvarian Cancer, Primary Peritoneal Cavity Cancer

Updated: 2013-07-09

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

CompletedNCT00006230

European Organisation for Research and Treatment of Cancer - EORTCOvarian Cancer

Start: 2000-05-31Updated: 2012-09-24

Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer

CompletedNCT00006082

European Organisation for Research and Treatment of Cancer - EORTCLung Cancer

Start: 2000-05-31Updated: 2012-09-24

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

Astex Pharmaceuticals, Inc.Esophageal Cancer, Gastric Cancer

Start: 2000-04-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

Astex Pharmaceuticals, Inc.Colorectal Cancer

Start: 1999-09-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

CompletedNCT00006026

European Organisation for Research and Treatment of Cancer - EORTCBladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer

Start: 2000-05-31Updated: 2012-09-24

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

CompletedNCT00005872

Astex Pharmaceuticals, Inc.Lung Cancer

Start: 1999-05-31End: 2004-04-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

CompletedNCT00005875

Astex Pharmaceuticals, Inc.Melanoma (Skin)

Start: 1999-01-31End: 2004-04-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

CompletedNCT00005873

Astex Pharmaceuticals, Inc.Breast Cancer

Start: 1999-09-30End: 2004-04-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

CompletedNCT00005874

Astex Pharmaceuticals, Inc.Gastrointestinal Stromal Tumor, Sarcoma, Small Intestine Cancer

Start: 1999-06-30End: 2004-04-30Updated: 2013-12-04

Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme

CompletedNCT00005826

European Organisation for Research and Treatment of Cancer - EORTCBrain and Central Nervous System Tumors

Start: 2000-03-31Updated: 2012-09-24

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

TerminatedNCT00113256

Astex Pharmaceuticals, Inc.Pancreatic Cancer

Start: 2005-02-28Updated: 2024-08-02

Phase 3

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Astex Pharmaceuticals, Inc.Pancreatic Cancer

Start: 1998-11-30Updated: 2013-12-04

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Astex Pharmaceuticals, Inc.Pancreatic Cancer

Start: 1999-03-31Updated: 2013-12-04

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Astex Pharmaceuticals, Inc.Pancreatic Cancer

Start: 1998-11-30Updated: 2013-12-04